Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2023-09-29 Declaration of Voting R…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release (2917 characters) announcing a change in the total number of shares and votes in Alligator Bioscience AB due to the exercise of warrants. It explicitly states the new total share count as of September 29, 2023. This type of announcement, detailing changes in the capital structure (specifically the number of shares outstanding), aligns best with the 'Share Issue/Capital Change' definition. Although it is a press release, the core content is a definitive update on share count, making 'SHA' more specific than the general 'RPA' or 'RNS'. The document is not an announcement *about* a report, but the report/update itself regarding capital structure.
2023-09-29 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces a 'CHANGE IN NUMBER OF SHARES AND VOTES' due to the exercise of warrants following a rights issue. This directly relates to changes in the company's capital structure and outstanding shares. The filing category 'Share Issue/Capital Change' (SHA) is the most appropriate fit for reporting changes in the total number of shares outstanding. Although it is a short announcement, the content is a specific regulatory update about share count, not just a general announcement of a report's publication (RPA/RNS).
2023-09-29 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding ('Reason for major shareholding notification Sell') by Avanza Bank Holding AB for its pension subsidiary, specifically noting the resulting percentage of voting rights and shares held (4.77295% and 29,767,478 shares). It explicitly mentions 'Resulting distribution of total holdings' and 'Group total holdings'. This structure and content directly correspond to a notification regarding changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is short and appears to be the notification itself, not an announcement of a larger report.
2023-08-21 English
Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Alligator Bioscience has received Orphan Designation from the European Medicines Agency for its drug candidate, mitazalimab. It provides details on the drug's mechanism, clinical trial status (OPTIMIZE-1), and regulatory implications. As it is a general corporate announcement regarding regulatory status and business development that does not fit into specific categories like financial reports or shareholder voting, it is classified as a Regulatory Filing (RNS).
2023-08-21 English
Alligator Bioscience erhåller särläkemedelsklassificering från den europeiska läkemedelsmyndigheten EMA för mitazalimab i bukspottkörtelcancer
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Alligator Bioscience received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its drug candidate mitazalimab concerning pancreatic cancer. It details the significance of the designation, mentions previous FDA ODD, provides clinical trial updates (OPTIMIZE-1), and concludes with boilerplate company information and contact details. The final section explicitly mentions an attached PDF file: "Bifogade filer: [Alligator Bioscience erhåller särläkemedelsklassificering från den europeiska läkemedelsmyndigheten EMA för mitazalimab i bukspottkörtelcancer]...". Since this is an announcement about a regulatory event (ODD approval) and not the full regulatory filing itself (like 10-K or AR), and it is structured as a news release, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant corporate news announcements that aren't covered by more specific codes like ER or CAP. It is not a Report Publication Announcement (RPA) because it is announcing a regulatory decision, not the publication of a financial report.
2023-08-21 Swedish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document details a change in shareholding percentage by a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Alligator Bioscience AB, explicitly stating the 'Before the transaction' and 'After the transaction' quantities and resulting percentages. The text mentions 'Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet' (Flagging occurs for crossing a threshold regarding the aggregated holding). This structure—reporting changes in ownership that cross regulatory notification thresholds (like 5%)—is characteristic of a Major Shareholding Notification. This aligns perfectly with the definition for 'Major Shareholding Notification' (Code: MRQ). The document is short and contains specific transaction details, not a general regulatory announcement (RNS) or a report itself.
2023-08-10 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.